Treat early and embrace the evidence in favour of anti-TNF-α therapy for Behçet's uveitis

British Journal of Ophthalmology

Volumn 94, Issue 3, 2010, Pages 269-270

  Lee, Richard W J ^a   Dick, Andrew D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNE DISEASE; BEHCET DISEASE; BIOLOGICAL THERAPY; BLINDNESS; CONSERVATIVE TREATMENT; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE CONTROL; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY INTERVENTION; EDITORIAL; EXPERIMENTAL MODEL; EYE DISEASE; GINGIVA HYPERPLASIA; HEADACHE; HEALTH CARE PERSONNEL; HIRSUTISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; MORTALITY; NEPHROTOXICITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RETINA; RETINA VASCULITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; TREATMENT DURATION; TUBERCULOSIS; UVEITIS; UVEORETINITIS; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 77949525151     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.176750     Document Type: Editorial

References (11)

1. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet's disease. Br J Ophthalmol 2010;94:282-6.
2. Dick AD, Forrester JV, Liversidge J, et al. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23:617-37.
3. Dick AD, McMenamin PG, Körner H, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 1996;26:1018-25.
4. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
6. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
7. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988;20(3 Suppl 4):136-43.
8. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41.
9. Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 2009;360:1925-7.
10. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480.
11. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880e5.